시장보고서

상품코드

1790314

임상 종양 차세대 시퀀싱 시장 규모, 점유율, 동향 분석 보고서 : 워크플로우별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033

발행일: 2025년 07월 | 리서치사:

Grand View Research | 페이지 정보: 영문 125 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

임상 종양 차세대 염기서열 분석 시장 현황 요약

세계 임상 종양 차세대 시퀀싱 시장 규모는 2024년 4억 8,230만 달러로 평가되었습니다. 2033년에는 19억 3,020만 달러에 달하고, 2025-2033년 16.77%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 임상 종양 차세대 염기서열 분석(NGS) 산업의 성장을 이끄는 주요 요인은 기술 발전 증가, 기업간 경쟁 심화, 의료비 지출 증가, 암 유병률 증가 등입니다.

또한, 솔루션 발명을 위한 R&D 활동의 강화는 예측 기간 동안 시장 성장을 가속할 것으로 예측됩니다.

테크놀러지 부문 대시보드
세계의 임상 종양 차세대 시퀀싱 시장 기술 변동 분석, 2024년 및 2033년
세계의 임상 종양 차세대 시퀀싱 시장 규모와 동향 분석(기술별, 2021-2033년)
전장 유전체 배열 분석
전장 엑솜 시퀀싱
타겟 시퀀싱 및 리시켄싱

제6장 임상 종양 차세대 시퀀싱 시장 : 용도 비즈니스 분석

용도 부문 대시보드
세계의 임상 종양 차세대 시퀀싱 시장 용도 변동 분석, 2024년 및 2033년
세계의 임상 종양 차세대 시퀀싱 시장 규모와 동향 분석(용도별, 2021-2033년)
스크리닝
동반진단
기타

제7장 임상 종양 차세대 시퀀싱 시장 : 최종 용도 비즈니스 분석

최종 용도 부문 대시보드
세계의 임상 종양 차세대 시퀀싱 시장 최종 용도 변동 분석, 2024년 및 2033년
세계의 임상 종양 차세대 시퀀싱 시장 규모와 동향 분석(최종 용도별, 2021-2033년)
클리닉
병원
연구소

제8장 임상 종양 차세대 시퀀싱 시장 : 지역별

지역별 시장 점유율 분석, 2024년 및 2033년
지역 시장 대시보드
시장 규모, 예측, 동향 분석, 2021-2033년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제9장 경쟁 구도

기업/경쟁 분류
전략 매핑
기업 시장 현황 분석, 2024년
기업 개요/상장기업
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Myriad Genetics
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies, Inc.
- Perkin Elmer
- Pacific Bioscience
- Oxford Nanopore Technologies Ltd.
- Eurofins Scientific SE
- Qiagen NV

LSH 25.08.25

Clinical Oncology Next Generation Sequencing Market Summary

The global clinical oncology next generation sequencing market size was estimated at USD 482.3 million in 2024 and is projected to reach USD 1,930.2 million by 2033, growing at a CAGR of 16.77% from 2025 to 2033. The key drivers responsible for the growth of the clinical oncology next generation sequencing (NGS) industry are increasing technological advancements, growing competition among players, increasing healthcare spending, and the rise in the prevalence of cancer.

In addition, augmenting research & development activities to invent solutions is expected to fuel the market growth over the forecast period.

Global Clinical Oncology Next Generation Sequencing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and analyzes the latest industry trends in each sub-segment from 2021 to 2033. Grand View Research has segmented the global clinical oncology next generation sequencing market report based on workflow, technology, application, end use, and region.

Workflow Outlook (Revenue, USD Million, 2021 - 2033)
NGS Pre-Sequencing
NGS Sequencing
NGS Data Analysis
Technology Outlook (Revenue, USD Million, 2021 - 2033)
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing
Application Outlook (Revenue, USD Million, 2021 - 2033)
Screening
- Sporadic Cancer
- Inherited Cancer
Companion Diagnostics
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals
Clinics
Laboratories
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Market Definitions
- 1.2.1. Workflow Segment
- 1.2.2. Technology Segment
- 1.2.3. Application Segment
- 1.2.4. End Use Segment
1.3. Information analysis
- 1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
- 1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segmental Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, and Scope

3.1. Market Lineage
- 3.1.1. Parent Market Analysis
- 3.1.2. Ancillary Market Analysis
3.2. Clinical Oncology NGS Market- Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Market Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTLE Analysis
- 3.3.3. COVID-19 Impact Analysis

Chapter 4. Clinical Oncology NGS Market: Workflow Business Analysis

4.1. Workflow Segment Dashboard
4.2. Global Clinical Oncology NGS Market Workflow Movement Analysis, 2024 & 2033
4.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
4.4. NGS Pre-Sequencing
- 4.4.1. Global NGS Pre-Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
4.5. NGS Sequencing
- 4.5.1. Global NGS Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. NGS Data Analysis
- 4.6.1. Global NGS Data Analysis Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Clinical Oncology NGS Market: Technology Business Analysis

5.1. Technology Segment Dashboard
5.2. Global Clinical Oncology NGS Market Technology Movement Analysis, 2024 & 2033
5.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
5.4. Whole Genome Sequencing
- 5.4.1. Global Whole Genome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
5.5. Whole Exome Sequencing
- 5.5.1. Global Whole Exome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
5.6. Targeted Sequencing & Resequencing
- 5.6.1. Global Targeted Sequencing & Resequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Clinical Oncology NGS Market: Application Business Analysis

6.1. Application Segment Dashboard
6.2. Global Clinical Oncology NGS Market Application Movement Analysis, 2024 & 2033
6.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Screening
- 6.4.1. Global Screening Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.5. Companion Diagnostics
- 6.5.1. Global Companion Diagnostics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 6.5.2. Sporadic Cancer
  - 6.5.2.1. Global Sporadic Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 6.5.3. Inherited Cancer
  - 6.5.3.1. Global Inherited Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Global Others Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Clinical Oncology NGS Market: End Use Business Analysis

7.1. End Use Segment Dashboard
7.2. Global Clinical Oncology NGS Market End Use Movement Analysis, 2024 & 2033
7.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
7.4. Clinics
- 7.4.1. Global Clinics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
7.5. Hospitals
- 7.5.1. Global Hospitals Market Estimates And Forecasts, 2021 - 2033 (USD Million)
7.6. Laboratories
- 7.6.1. Global Laboratories Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Clinical Oncology NGS Market: Regional Estimates & Trend Analysis by Workflow, Technology, Application, and End Use

8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts, Trend Analysis, 2021 to 2033:
8.4. North America
- 8.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key country dynamics
  - 8.4.2.2. Competitive scenario
  - 8.4.2.3. Regulatory framework
  - 8.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key country dynamics
  - 8.4.3.2. Competitive scenario
  - 8.4.3.3. Regulatory framework
  - 8.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key country dynamics
  - 8.4.4.2. Competitive scenario
  - 8.4.4.3. Regulatory framework
  - 8.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Europe
- 8.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Competitive scenario
  - 8.5.2.3. Regulatory framework
  - 8.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key country dynamics
  - 8.5.3.2. Competitive scenario
  - 8.5.3.3. Regulatory framework
  - 8.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key country dynamics
  - 8.5.4.2. Competitive scenario
  - 8.5.4.3. Regulatory framework
  - 8.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key country dynamics
  - 8.5.5.2. Competitive scenario
  - 8.5.5.3. Regulatory framework
  - 8.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key country dynamics
  - 8.5.6.2. Competitive scenario
  - 8.5.6.3. Regulatory framework
  - 8.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.7. Denmark
  - 8.5.7.1. Key country dynamics
  - 8.5.7.2. Competitive scenario
  - 8.5.7.3. Regulatory framework
  - 8.5.7.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.8. Sweden
  - 8.5.8.1. Key country dynamics
  - 8.5.8.2. Competitive scenario
  - 8.5.8.3. Regulatory framework
  - 8.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.9. Norway
  - 8.5.9.1. Key country dynamics
  - 8.5.9.2. Competitive scenario
  - 8.5.9.3. Regulatory framework
  - 8.5.9.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Competitive scenario
  - 8.6.2.3. Regulatory framework
  - 8.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key country dynamics
  - 8.6.3.2. Competitive scenario
  - 8.6.3.3. Regulatory framework
  - 8.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key country dynamics
  - 8.6.4.2. Competitive scenario
  - 8.6.4.3. Regulatory framework
  - 8.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key country dynamics
  - 8.6.5.2. Competitive scenario
  - 8.6.5.3. Regulatory framework
  - 8.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key country dynamics
  - 8.6.6.2. Competitive scenario
  - 8.6.6.3. Regulatory framework
  - 8.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key country dynamics
  - 8.6.7.2. Competitive scenario
  - 8.6.7.3. Regulatory framework
  - 8.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
8.7. Latin America
- 8.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Competitive scenario
  - 8.7.2.3. Regulatory framework
  - 8.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key country dynamics
  - 8.7.3.2. Competitive scenario
  - 8.7.3.3. Regulatory framework
  - 8.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
8.8. MEA
- 8.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key country dynamics
  - 8.8.2.2. Competitive scenario
  - 8.8.2.3. Regulatory framework
  - 8.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key country dynamics
  - 8.8.3.2. Competitive scenario
  - 8.8.3.3. Regulatory framework
  - 8.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key country dynamics
  - 8.8.4.2. Competitive scenario
  - 8.8.4.3. Regulatory framework
  - 8.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key country dynamics
  - 8.8.5.2. Competitive scenario
  - 8.8.5.3. Regulatory framework
  - 8.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
- 9.4.1. Thermo Fisher Scientific Inc.
  - 9.4.1.1. Company overview
  - 9.4.1.2. Financial performance
  - 9.4.1.3. Product benchmarking
  - 9.4.1.4. Strategic initiatives
- 9.4.2. Illumina, Inc.
  - 9.4.2.1. Company overview
  - 9.4.2.2. Financial performance
  - 9.4.2.3. Product benchmarking
  - 9.4.2.4. Strategic initiatives
- 9.4.3. Myriad Genetics
  - 9.4.3.1. Company overview
  - 9.4.3.2. Financial performance
  - 9.4.3.3. Product benchmarking
  - 9.4.3.4. Strategic initiatives
- 9.4.4. F. Hoffmann-La Roche Ltd.
  - 9.4.4.1. Company overview
  - 9.4.4.2. Financial performance
  - 9.4.4.3. Product benchmarking
  - 9.4.4.4. Strategic initiatives
- 9.4.5. Agilent Technologies, Inc.
  - 9.4.5.1. Company overview
  - 9.4.5.2. Financial performance
  - 9.4.5.3. Product benchmarking
  - 9.4.5.4. Strategic initiatives
- 9.4.6. Perkin Elmer
  - 9.4.6.1. Company overview
  - 9.4.6.2. Financial performance
  - 9.4.6.3. Product benchmarking
  - 9.4.6.4. Strategic initiatives
- 9.4.7. Pacific Bioscience
  - 9.4.7.1. Company overview
  - 9.4.7.2. Financial performance
  - 9.4.7.3. Product benchmarking
  - 9.4.7.4. Strategic initiatives
- 9.4.8. Oxford Nanopore Technologies Ltd.
  - 9.4.8.1. Company overview
  - 9.4.8.2. Financial performance
  - 9.4.8.3. Product benchmarking
  - 9.4.8.4. Strategic initiatives
- 9.4.9. Eurofins Scientific S.E.
  - 9.4.9.1. Company overview
  - 9.4.9.2. Financial performance
  - 9.4.9.3. Product benchmarking
  - 9.4.9.4. Strategic initiatives
- 9.4.10. Qiagen N.V.
  - 9.4.10.1. Company overview
  - 9.4.10.2. Financial performance
  - 9.4.10.3. Product benchmarking
  - 9.4.10.4. Strategic initiatives